ROPES GRAY

RECEIVED CENTRAL FAX CENTER

Ø1006/027

Docket No.: BOS/3

SEP 1 3 2006

Application No. 09/699,224 Amendment dated September 13, 2006 After Final Office Action of December 29, 2005

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in this application.

**Listing of Claims:** 

Claim 1 (currently amended): An isolated peptide mimic of a conserved gonococcal lipo-

oligosaccharide (LOS) epitope not found on human blood group antigens, wherein said peptide

mimic is capable of inducing in a mammal an immune response against said conserved

gonococcal lipo-oligosaccharide (LOS) epitope and wherein said peptide mimic comprises the

amino acid sequence of SEQ ID NO:1 is less than 50 amino acids in length.

Claim 2 Cancelled.

Claim 3 (original): The peptide mimic according to claim 1, wherein the immune response is T-

cell dependent.

Claim 4 (currently amended): The peptide mimic according to claim 1-or 2, wherein the amino

acid sequence of the peptide mimic comprises cysteine residues at each terminus.

Claim 5 (previously presented): The peptide mimic according to claim 4, wherein a cyclic

peptide is formed through disulfide bridges between the cysteine residues at each terminus of

said amino acid sequence.

Claim 6 (previously amended): The peptide mimic according to claim 5, wherein the peptide

mimic is coupled to a second agent.

Claim 7 (original): The peptide mimic according to claim 6, wherein the second agent is an

adjuvant.

10189465\_1

2

Docket No.: BOS/3

Application No. 09/699,224

Amendment dated September 13, 2006

After Final Office Action of December 29, 2005

Claim 8 (currently amended): The peptide mimic according to claim 1 er 2, wherein the peptide

mimic further comprises an adjuvant or a carrier protein.

Claim 9 (currently amended): The peptide mimic according to claim 1 or 2, wherein the peptide

mimic is part of a multiple-antigen peptide (MAP).

Claim 10 (currently amended): The peptide mimic according to claim 1 of 2, wherein said

peptide mimic competes with gonococcal lipooligosaccharide (LOS) for binding to monoclonal

antibody 2C7.

Claim II: Cancelled.

Claim 12 (previously presented): The peptide mimic according to claim 1, wherein the peptide

mimic immunospecifically binds to monoclonal antibody 2C7.

Claim 13 (currently amended): The peptide mimic according to claim 1, wherein the peptide

mimic immunospecifically binds to a monoclonal antibody produced by immunizing a mammal

with an anti-idiotypic monoclonal antibody, or antigen-binding fragment thereof, produced by a

hybridoma cell line having the specific immunological reactivity of  $\underline{a}$  monoclonal  $\underline{antibody}$ 

antibodies produced by hybridoma cell line HB 11311 as deposited with the ATCC.

Claim 14: Cancelled.

Claim 15 (currently amended): A composition for immunizing against N. gonorrhoeae infection

comprising an immunoprophylactically effective amount of a peptide mimic according to any

one of claims 1, 3, [[1-3]], 5-7, 12 and or 13.

10189465\_I

3

Docket No.: BOS/3

Application No. 09/699,224 Amendment dated September 13, 2006 After Final Office Action of December 29, 2005

Claim 16 (previously presented): A composition for immunizing against N. gonorrhoeae infection comprising an immunoprophylactically effective amount of a peptide mimic comprising the amino acid sequence of SEQ ID NO:1.

Claims 17-23 Cancelled.

Claim 24 (withdrawn/currently amended): A method for immunizing a mammal against N. gonorrhoeae infection comprising the step of administering to said mammal an immunoprophylactically effective amount of a peptide mimic according to claim 1 or claim 3 any one of claims 1 3 and a pharmaceutically acceptable carrier.

Claim 25 (withdrawn/currently amended): A method for immunizing a mammal against N. gonorrhoeae infection comprising the step of administering to said mammal an immunoprophylactically effective amount of a peptide mimic according to claim 12 or claim 13 any one of claims 11-14 and a pharmaceutically acceptable carrier.

Claim 26 (withdrawn/currently amended): The peptide mimic according to claim 1-or 11, wherein the peptide mimic is coupled to a complement protein.

Claim 27 (withdrawn): The peptide mimic according to claim 26, wherein the peptide mimic is coupled to complement protein C3d.

Claim 28 (withdrawn): A method for immunizing a mammal against N. gonorrhoeae infection comprising the step of administering to said mammal an immunoprophylactically effective amount of a peptide mimic according to claim 27 and a pharmaceutically acceptable carrier.

## BEST AVAILABLE COPY

Application No. 09/699,224

Amendment dated September 13, 2006

After Final Office Action of December 29, 2005 \*\*\* •

Docket No.: BOS/3

Claim 29 (withdrawn): A composition for immunizing against *N. gonorrhoeae* infection comprising an immunoprophylactically effective amount of a peptide mimic according to claim 27.

Claim 30 (withdrawn/currently amended): A method for increasing the antigenicity of a peptide mimic according to claim 1 or 11 comprising the step of coupling said peptide mimic to a complement protein.

Claim 31 (withdrawn): The method according to claim 30, wherein the complement protein is C3d.